Stevens Capital Management LP Reduces Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Stevens Capital Management LP reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,223 shares of the company’s stock after selling 1,598 shares during the period. Stevens Capital Management LP’s holdings in IDEXX Laboratories were worth $656,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the 2nd quarter worth approximately $29,000. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. NewSquare Capital LLC lifted its position in shares of IDEXX Laboratories by 87.5% during the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after buying an additional 35 shares in the last quarter. WPG Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth about $37,000. Finally, Bank of Jackson Hole Trust increased its stake in IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after buying an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDXX shares. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Wednesday. BTIG Research increased their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley upped their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $730.50.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 5.3%

IDXX stock opened at $725.91 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a fifty day moving average of $656.12 and a 200-day moving average of $595.80. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $735.59. The stock has a market capitalization of $57.96 billion, a PE ratio of 60.44, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $2.80 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.